Human Body & Medicine18 Concepts & Facts

Monoclonal Antibody GK Facts, Overview & Study Guide

Reviewed by the Master10 Editorial Board for accuracy, clarity and competitive-exam relevance.Editorial Policy

A Monoclonal Antibody (mAb) is a laboratory-engineered, homogeneous population of Immunoglobulin (Ig) glycoprotein molecules produced by a single immortalized clone of B-lymphocytes, designed to bind with lock-and-key specificity to one single antigenic determinant (epitope) on a target pathogen, toxin, or cancer cell. In a natural immune response to an infection or vaccine, the human body mounts a Polyclonal Antibody response: dozens of different B-cell lineages proliferate simultaneously, secreting a heterogeneous mixture of antibodies that recognize multiple different epitopes across the pathogen's surface. While polyclonal antisera are effective for broad immunity, their batch-to-batch variability and cross-reactivity limited their precision as targeted therapeutics until 1975, when German immunologist Georges Köhler and Argentine-British biochemist César Milstein at the MRC Laboratory of Molecular Biology in Cambridge invented Hybridoma Technology—a breakthrough awarded the 1984 Nobel Prize in Physiology or Medicine (shared with Niels Kaj Jerne).

To manufacture monoclonal antibodies via classical Hybridoma Technology, a mouse is first immunized with a specific target antigen, and antibody-producing splenic B-lymphocytes (which possess the desired antigen specificity but have a finite lifespan of only a few days in culture) are harvested. These B-cells are chemically or electrically fused using Polyethylene Glycol (PEG) with immortal Myeloma (bone marrow B-cell cancer) cells that lack the salvage-pathway enzyme HGPRT (Hypoxanthine-Guanine Phosphoribosyltransferase). The fused cell mixture is cultured in selective HAT Medium (Hypoxanthine–Aminopterin–Thymidine): aminopterin blocks de novo DNA synthesis, killing unfused HGPRT-negative myeloma cells, while unfused normal B-cells die naturally after a few days. Only the fused Hybridoma cells survive—inheriting epitope-specific antibody production from the B-cell and unlimited division immortality from the myeloma cell.

Historically heralded by Nobel Laureate Paul Ehrlich around 1900 as theoretical **'Zauberkugeln' ('Magic Bullets') that could seek out disease targets without harming healthy tissue, monoclonal antibodies have grown into the largest class of modern biopharmaceutical drugs. From blocking checkpoint inhibitors (PD-1 / CTLA-4) in oncology and neutralizing HER2-positive breast cancer* (Trastuzumab) to treating rheumatoid arthritis (Adalimumab) and providing immediate post-exposure prophylaxis against Rabies and Nipah virus*, mAbs underpin 21st-century precision medicine.

Key Concepts & Self-Assessment18 Key Facts

Review key Monoclonal Antibody exam facts and rate your mastery to track revision.

Progress: 0/18 Rated 0 Mastered 0 Review Later

Core Immunological Distinction — Monoclonal vs. Polyclonal: Monoclonal antibodies (mAbs) derive from a single B-cell clone and bind exclusively to one specific epitope; Polyclonal antibodies derive from multiple B-cell lineages and bind to multiple different epitopes on the same antigen.

Invention of Hybridoma Technology (1975 & 1984 Nobel Prize): Invented in 1975 by Georges Köhler and César Milstein (who famously chose not to patent the technique so humanity could benefit freely), winning the 1984 Nobel Prize in Physiology or Medicine.

Paul Ehrlich's 'Magic Bullet' (Zauberkugeln) Concept: Formulated by Paul Ehrlich (1908 Nobel Laureate), envisioning therapeutic agents that selectively target disease-causing organisms or tumors while sparing healthy host cells.

Hybridoma Cell Fusion Partners: Fuses an Antigen-stimulated Spleen B-Lymphocyte (provides specific antibody gene rearrangement; short-lived) with an HGPRT-deficient Myeloma Cell (provides cellular immortality; cannot synthesize antibodies).

Chemical Fusogen Used: Polyethylene Glycol (PEG) or electrofusion is used to merge the lipid bilayers of the B-lymphocyte and the myeloma cell into a single binucleate/synkaryon hybridoma.

Role of Selective HAT Medium: HAT Medium contains Hypoxanthine, Aminopterin, and Thymidine; Aminopterin is a folate antagonist that blocks the de novo purine/pyrimidine synthesis pathway, forcing cells to rely on the HGPRT salvage pathway—thus killing unfused HGPRT-negative myeloma cells.

First FDA-Approved Therapeutic Monoclonal Antibody (1986): Muromonab-CD3 (OKT3), a murine (mouse) anti-CD3 monoclonal antibody approved in 1986 to prevent acute kidney transplant rejection.

Overcoming the HAMA (Human Anti-Mouse Antibody) Problem: Early 100% mouse antibodies (-omab) triggered human immune rejection (HAMA response); recombinant DNA engineering progressively replaced mouse constant domains with human IgG sequences.

WHO International Nonproprietary Name (INN) Stem Nomenclature: (1) *-omab = 100% Murine (Mouse) (0% human, e.g., Muromonab); (2) -ximab = Chimeric (~65% human constant + 35% mouse variable region, e.g., Rituximab, Infliximab); (3) -zumab = Humanized (>90% human + only mouse CDR loops, e.g., Trastuzumab, Bevacizumab); (4) -umab = 100% Fully Human (generated via phage display or transgenic mice, e.g., Adalimumab, Nivolumab*).

#10

Phage Display & Transgenic Mice (2018 Nobel Prize): Sir Gregory P. Winter and George P. Smith received the 2018 Nobel Prize in Chemistry for developing Phage Display of antibodies, enabling the creation of the world's first fully human blockbuster mAb, *Adalimumab (Humira)*.

#11

Cancer Checkpoint Inhibitor Immunotherapy (2018 Nobel Prize): James P. Allison and Tasuku Honjo won the 2018 Nobel Prize in Physiology or Medicine for discovering how monoclonal antibodies blocking *CTLA-4 (Ipilimumab) and PD-1 (Nivolumab, Pembrolizumab)* release the 'brakes' on host T-cells to destroy solid tumors.

#12

Antibody-Drug Conjugates (ADCs — 'Biological Guided Missiles'): Links a tumor-seeking monoclonal antibody (such as Trastuzumab) via a chemical linker to a potent cytotoxic chemotherapy payload (such as Deruxtecan), releasing the poison only inside the cancer cell.

#13

Diagnostic Lateral Flow & Pregnancy Tests: Home urine pregnancy test kits and rapid antigen cards rely on immobilized monoclonal antibodies specific to the **

eta

-subunit of Human Chorionic Gonadotropin (

eta

-hCG)** or viral nucleocapsid proteins.

#14

Infectious Disease Neutralization (Rabies, Nipah & Ebola): India developed and deployed Rabishield (SII RMab), the world's first human monoclonal antibody for post-exposure Rabies prophylaxis, and sourced experimental m102.4 monoclonal antibody during Kerala Nipah virus outbreaks.

#15

Predominant Immunoglobulin Isotype Used: Nearly all therapeutic monoclonal antibodies are engineered on the Immunoglobulin G (specifically IgG1 or IgG4) backbone (~150 kDa Y-shaped tetramer with two Heavy and two Light chains) due to its long 21-day serum half-life.

#16

Mechanisms of Cell Killing (ADCC & CDC): Therapeutic IgG1 mAbs kill target cells via Antibody-Dependent Cellular Cytotoxicity (ADCC) (recruiting Natural Killer [NK] cells via Fc

gamma

RIIIa receptors) and Complement-Dependent Cytotoxicity (CDC).

#17

Indigenous Indian Biosimilar mAb Ecosystem: Indian biopharma leaders (Biocon, Zydus Lifesciences, Dr. Reddy's, Serum Institute, Intas) are global pioneers in manufacturing affordable biosimilar monoclonal antibodies (Trastuzumab, Rituximab, Bevacizumab) under CDSCO's 2016 Similar Biologics Guidelines.

#18

Bispecific Antibodies (BsAbs): Next-generation engineered antibodies (such as Blinatumomab) featuring two different antigen-binding arms—one grabbing a CD3+ T-cell and the other grabbing a CD19+ leukemia B-cell to force immune synapse destruction.

Subject Specialist Commentary

Analytical perspective & practical exam advice from the Master10 academic board

Educator's Insight

When a virus enters your body, your immune system activates dozens of different B-cells to produce a mixed soup of Polyclonal Antibodies attaching to different spots on the germ. In 1975, Georges Köhler and César Milstein figured out how to fuse a single antibody-producing B-cell with an immortal myeloma cancer cell inside HAT medium, creating a Hybridoma factory that churns out billions of identical Monoclonal Antibodies (mAbs) aimed at one exact molecular target (epitope).

For UPSC Prelims and CDS/SSC Science exams, master the Four-Suffix Drug Code (-omab, -ximab, -zumab, -umab): -omab = 100% Mouse; -ximab = Chimeric (Mouse + Human); -zumab = Humanized (>90% Human, e.g., Trastuzumab for HER2 breast cancer); and -umab = 100% Fully Human (e.g., Adalimumab). Also remember m102.4, the monoclonal antibody imported by ICMR to treat Nipah virus in Kerala.

Monoclonal Antibody GK Facts, Overview & Study Guide

Key Concepts & Self-Assessment18 Key Facts

Subject Specialist Commentary

Related Knowledge Topics to Discover

Looking for more GK practice?